A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Clinical trial NCT05138146 · UNKNOWN
Trial details
- NCT number
- NCT05138146
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-30
- Primary completion
- 2023-11-30
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.